Lone Bredo Pedersen

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Christian H. Geisler, Arne Kolstad, Anna Laurell et al. · Blood · 2008 · 624 citations · Full text

Medicine, Hematology, Oncology +13

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Christian Winther Eskelund, Christina Dahl, Jakob Werner Hansen et al. · Blood · 2017 · 396 citations · Full text

Medicine, Hematology, Oncology +14

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

Andreas Agathangelidis, Nikos Darzentas, Anastasia Hadzidimitriou et al. · Blood · 2012 · 387 citations · Full text

Life Sciences, Immunology, Oncology +17

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

Mohammed Farooqui, Janet Valdez, Sabrina Martyr et al. · The Lancet Oncology · 2014 · 366 citations · Full text

Medicine, Immunology, Oncology +11

Nordic <scp>MCL</scp>2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by <scp>BEAM</scp> or <scp>BEAC</scp> + autologous stem‐cell support: still very long survival but late relapses do occur

Christian H. Geisler, Arne Kolstad, Anna Laurell et al. · British Journal of Haematology · 2012 · 272 citations

Medicine, Immunology, Oncology +13